An Open Label, Long Term Safety Trial of BI 655130 Treatment in Patients With Moderate to Severely Active Ulcerative Colitis Who Have Completed Previous BI 655130 Trials
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Spesolimab (Primary) ; Spesolimab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 13 Nov 2018 Status changed from not yet recruiting to recruiting.
- 15 Oct 2018 Planned initiation date changed from 15 Oct 2018 to 29 Oct 2018.
- 17 Sep 2018 Planned initiation date changed from 1 Oct 2018 to 15 Oct 2018.